Magnesium
Magnesium (chemical or element symbol Mg) is an essential mineral in the human body. It plays a key role in DNA and RNA synthesis and in the production of ATP. It is a cofactor in more than 300 enzyme systems.[1]
Role in the body[edit | edit source]
Deficiency[edit | edit source]
Symptoms of magnesium deficiency include loss of appetite, nausea, vomiting, fatigue, and weakness. As magnesium deficiency worsens, numbness, tingling, muscle contractions and cramps, seizures, personality changes, abnormal heart rhythms, and coronary spasms can occur. Severe magnesium deficiency can result in hypocalcemia or hypokalemia (low serum calcium or potassium levels, respectively) because mineral homeostasis is disrupted.[1]
People with gastrointestinal[1] disorders and chronic fatigue syndrome are at higher risk of magnesium deficiency.
Deficiency increases the risk of osteoporosis. Magnesium supplementation may help prevent migraine.[1]
Forms of administration[edit | edit source]
Magnesium may be taken as an oral supplement but may not be well absorbed. Other forms of magnesium administration include transdermal magnesium and intramuscular magnesium injections.
Magnesium is hypotonic. Administration can cause water to flow into cells in the local area where it is applied, which can cause a temporary stinging sensation.
In human disease[edit | edit source]
Chronic Fatigue Syndrome[edit | edit source]
In 1991, Cox et al., performed a randomized, double-blind, placebo-controlled trial of 20 United Kingdom CFS patients finding that the subjects with CFS had lower red blood cell magnesium than healthy controls. Patients treated with intramuscular magnesium sulphate for six weeks had higher self-reported energy levels, better emotional state and less pain on the Nottingham health profile when compared to placebo.[2]
In contrast, three subsequent case‐report studies, two in the UK (Clague et al., 1992[3] and Hinds et al., 1994[4]), and one in the Netherlands (Swanink et al., 1995[5]), did not find magnesium deficiency in CFS trial subjects.
A 2014 study found magnesium transporter issues were linked to chronic Epstein-Barr virus infection, decreased Natural killer cell function, and neoplasia (sometimes-cancerous growths). [6] This disorder, termed 'X-MEN' (for X-linked, EBV, and neoplasia) was identified as a recessive, X-linked disorder that would therefore be many times more common in men. Due to magnesium's role as a 'second messenger', this magnesium transporter disorder also would result in a primary immunodeficiency that would worsen with age. [6] Patients also have impaired T-cell activation and decreased natural killer (NK) cell function due to a decreased expression of "the NK stimulatory receptor 'natural-killer group 2, member D' (NKG2D)."[7] Although T-cells are affected, there is no direct evidence of B-cell effects in X-MEN disease.[7]
Since chronic Epstein-Barr virus infection has been associated with chronic fatigue syndrome, this error in magnesium transport may be worth considering in male patients, especially with slow onset and history of childhood infection.[6]
Mast cell activation disorder[edit | edit source]
Magnesium is a cofactor in the production of diamine oxidase. It is an enzyme that breaks down histamine, which is released by mast cells.
Learn more[edit | edit source]
Further reading[edit | edit source]
Magnesium-Linus Pauling Institute Micronutrient Information Center
See also[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 1.2 1.3 Magnesium: Fact sheet for health professionals, National Institutes of Health: Office of Dietary Supplements, March 2, 2018, retrieved May 22, 2018
- ↑ I.M., Cox; M.J., Campbell; D., Dowson (1991), "Red blood cell magnesium and chronic fatigue syndrome", The Lancet, doi:10.1016/0140-6736(91)91371-Z, PMID 1672392
- ↑ Clague JE, Edwards RH, Jackson MJ (1992). Intravenous magnesium loading in chronic fatigue syndrome. Lancet 340: 124–125. PMID:1352002
- ↑ Hinds G, Bell NP, McMaster D, McCluskey DR (1994). Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. Ann Clin Biochem 31 (Pt 5): 459–461. DOI:10.1177/000456329403100506
- ↑ Swanink CM, Vercoulen JH, Bleijenberg G, Fennis JF, Galama JM, van der Meer JW (1995). Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. J Intern Med 237: 499–506. PMID:7738491
- ↑ 6.0 6.1 6.2 Li, F.-Y.; Chaigne-Delalande, B; Su, H; Matthews, H; Lenardo, M.J. (2014), "XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.", Blood, doi:10.1182/blood-2013-11-538686
- ↑ 7.0 7.1 Ravell, J; Chaigne-Delalande, B; Lenardo, M (2014), "XMEN disease: a combined immune deficiency with magnesium defect.", Current Opinion in Pediatrics, doi:10.1097/MOP.0000000000000156
